Optimizing Cell Therapy to Defeat Cancer
We combine precision stem cell engineering and NK-activating antibodies to unlock the full potential of Natural Killer cells as a first line of defense against cancer.
Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2022, moving towards broad patient access to cancer-defeating cures."
Dr. Daniel Teper,
Cytovia Therapeutics CEO
Cytovia In The News
October 12th, 2021
